-

12:20:54 AM

APDN Stock News

APDN - Applied Dna Sciences Inc

05/12/22 4:05 PM

Nasdaq : APDN

earningslow float

Applied DNA Reports Second Quarter Fiscal 2022 Financial Results

Applied DNA Sciences, Inc., a leader in cell-free, enzymatic DNA production, today announced consolidated financial results for the second quarter of fiscal 2022, ended March 31, 2022. James A. Hayward, president and CEO of Applied DNA.“ Our clinical lab subsidiary, ADCL, continues to power our topline performance in the first half of fiscal 2022 with revenues that...

RHEA-AI

neutral

05/09/22 10:00 AM

Nasdaq : APDN

earningslow float

Applied DNA Schedules Fiscal 2022 Second Quarter Financial Results Conference Call and Webcast for Thursday, May 12, 2022

Applied DNA Sciences, Inc., a leader in cell-free, enzymatic DNA production, today announced that it will report fiscal 2022 second quarter financial results after market close on Thursday, May 12, 2022. The Company’ s management will discuss the results during a conference call and simultaneous webcast at 4:30 p.m. ET that same day. Presentation slides will...

RHEA-AI

neutral

04/06/22 9:00 AM

Nasdaq : APDN

low float

Applied DNA Awarded NYC-Based ‘Return-to-Office’

Applied DNA Sciences, Inc., a leader in cell-free, enzymatic DNA production, announced today that its wholly-owned clinical laboratory subsidiary, Applied DNA Clinical Labs, LLC, has been awarded a safeCircle™ health services contract from a New York City- based investment management firm. The contract provides for PCR-based COVID-19 testing and associated...

RHEA-AI

neutral

03/23/22 12:00 PM

Nasdaq : APDN

conferenceslow float

Applied DNA to Participate in the 2022 Virtual Growth Conference Presented by Maxim Group LLC and Hosted by M-Vest on March 28th – 30th from 9:00 a.m. - 5:00 p.m. EDT

Applied DNA Sciences, Inc., a leader in cell-free, enzymatic DNA production, today announced that CEO Dr. James A. Hayward is invited to present at the 2022 Virtual Growth Conference presented by Maxim Group LLC and hosted by M-Vest, on March 28 th- 30 th from 9:00 a.m.- 5:00 p.m. EDT. During the virtual conference, investors will hear from executives from a wide range...

RHEA-AI

neutral

03/14/22 8:00 AM

Nasdaq : APDN

low float

Applied DNA Executes LOI with Spindle Biotech for Research Collaboration on Simplified High Yield mRNA Production System

Applied DNA Sciences, Inc., a leader in cell-free, enzymatic DNA production, and Spindle Biotech Inc., a company focused on the development of a novel, high yield, and low-cost RNA production systems, today announced that the two companies have executed a non-binding letter of intent that outlines the terms of a collaborative research...

RHEA-AI

very positive

03/10/22 10:00 AM

Nasdaq : APDN

conferenceslow float

Applied DNA to Participate in Fireside Chat at the 34th Annual ROTH Investor Conference

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing and nucleic acid-based technologies, announced today that Chief Executive Officer Dr. James A. Hayward will host a virtual fireside chat with the Company's covering analyst, Managing Director and Senior Research Analyst Jonathan Aschoff, on Monday, March 14, 2022, at the...

RHEA-AI

neutral

02/24/22 5:50 PM

Nasdaq : APDN

offeringlow float

Applied DNA Announces Closing of $4.2 Million Registered Direct Offering

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing, announced today the closing of its previously announced registered direct offering with an institutional investor of 1,496,400 shares of common stock at a price of $2.80 per share for gross proceeds of approximately $4.2 million, before deducting the placement...

RHEA-AI

neutral

02/22/22 8:00 AM

Nasdaq : APDN

offeringlow float

Applied DNA Announces Pricing of $4.2 Million Registered Direct Offering

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing, announced today that it has entered into a securities purchase agreement with an institutional investor, providing for the purchase and sale of 1,496,400 shares of common stock at a price of $2.80 per share, in a registered direct offering, resulting in total gross...

RHEA-AI

neutral

02/17/22 9:00 AM

Nasdaq : APDN

clinical triallow float

Applied DNA and EvviVax Announce Publication of Positive Preclinical Data for LinearDNA™ Platform Approach to Cancer Immunotherapy

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing and nucleic...

RHEA-AI

neutral

02/10/22 4:05 PM

Nasdaq : APDN

earningslow float

Applied DNA First Quarter Fiscal 2022 Financial Results Feature Record Quarterly Revenues

Applied DNA Sciences, Inc., a leader in Polymerase Chain Reaction- based DNA manufacturing and nucleic acid-based technologies, today announced consolidated financial results for the first quarter of fiscal 2022, ended December 31, 2021. “The first quarter was also noteworthy for progress in positioning our LinearDNA platform as an alternative to plasmid...

RHEA-AI

positive

1 2 3 4 5 6 7 8 9 Next

APDN Data

IndustryCyclic Crude, Intermediate, and Gum and Wood Chemical Manufacturing
Websitehttps://adnas.com
CeoJames Hayward
Security nameApplied Dna Sciences Inc
Issue typecs
SectorManufacturing
Sic code2865
Employees60
Tags
- Health Technology
- Pharmaceuticals: Major
- Cyclic Crude
- Intermediate
- and Gum and Wood Chemical Manufacturing
- Miscellaneous Commercial Services
- Technology Services
- Commercial Services
- Manufacturing
- Information Technology Services
Address50 Health Sciences Dr
StateNew York
CityStony Brook
Zip11790-3349
CountryUS
Phone16312408800

About Applied Dna Sciences Inc

Applied DNA is commercializing LinearDNA™, its proprietary, large-scale polymerase chain reaction ('PCR')-based manufacturing platform that allows for the large-scale production of specific DNA sequences. The LinearDNA platform has utility in the nucleic acid-based in vitro diagnostics and preclinical nucleic acid-based drug development and manufacturing market. The platform is used to manufacture DNA for customers as components of in vitro diagnostic tests and for preclinical nucleic acid-based drug development in the fields of adoptive cell therapies (CAR T and TCR therapies), DNA vaccines (anti-viral and cancer), RNA therapies, clustered regularly interspaced short palindromic repeats (CRISPR) based therapies, and gene therapies. Applied DNA has also established a COVID-19 diagnostic and testing offering that is in the early stages of commercialization and is grounded in the Company's deep expertise in DNA. The LinearDNA platform also has non-biologic applications, such as supply chain security, anti-counterfeiting and anti-theft technology. Key end-markets include textiles, pharmaceuticals and nutraceuticals, and cannabis, among others.